Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.

Cancer chemotherapy and pharmacology - 1 Mar 2014

Burns K E, Goldthorpe M A, Porteus F, Browett P, Helsby N A

Abstract excerpt

PURPOSE: Previous reports indicate that discordance between CYP2C19 genotype and enzyme function occurs in up to 37 % of cancer patients with a range of solid tumours. The aim of this study was to determine whether this acquired loss of function in hepatic CYP2C19 activity also occurs in patients with haematological malignancy. METHODS: CYP2C19 genotype was determined in 25 patients with multiple myeloma using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Metabolism, Inborn Errors

Share to Multiple Myeloma

Share to Polymerase Chain Reaction

Share to Polymorphism, Restriction Fragment Length

Share to Proguanil

Source

Identifiers

PMID: 24519754
DOI: 10.1007/s00280-014-2409-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity.PMID 24519754Read ↗

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype.Semantic proximity Read ↗

High CYP2C19 phenotypic variability in gastrointestinal cancer patients.Semantic proximity Read ↗

CYP2C19*2 gene variant (G681A, rs4244285) as a prognostic marker for the clinical course of multiple myeloma.Semantic proximity Read ↗

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.Semantic proximity Read ↗

The impact of CYP2C19 genotype on phenoconversion by concomitant medicationSemantic proximity Read ↗

Identification and functional characterization of new potentially defective alleles of human CYP2C19.Semantic proximity Read ↗

Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction.Semantic proximity Read ↗

Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.Semantic proximity Read ↗

Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients.Semantic proximity Read ↗

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.Semantic proximity Read ↗

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.Semantic proximity Read ↗

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.